Literature DB >> 3519241

Treatment of essential hypertension with felodipine in combination with a diuretic.

T Hedner, O Samuelsson, E Sjögren, D Elmfeldt.   

Abstract

In a double-blind cross-over study, the effect on blood pressure (BP), heart rate (HR) and plasma noradrenaline concentration (pNA) of placebo or felodipine given in addition to hydrochlorothiazide was studied in 12 male patients with essential hypertension, not satisfactorily controlled with the diuretic alone. The first dose of felodipine decreased BP and increased HR for about 6 h. After 4 weeks of treatment with felodipine, BP was reduced for 24 h, whereas HR was only transiently increased. The elimination half-life of felodipine was about 23 h. The plasma noradrenaline concentration increased after felodipine and serum uric acid decreased. Side-effects were few and usually mild.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519241     DOI: 10.1007/bf00614290

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Indirect blood pressure and heart rate measured quickly without observer bias using a semi-automatic machine (auto-manometer)--response to isometric exercise in normal healthy males and its modification by beta-adrenoceptor blockade.

Authors:  G Nyberg
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  Haemodynamic effects of short and long term administration of felodipine in spontaneously hypertensive rats.

Authors:  M Nordlander
Journal:  Drugs       Date:  1985       Impact factor: 9.546

3.  Evaluation of a new antihypertensive agent. Minoxidil.

Authors:  M E Kosman
Journal:  JAMA       Date:  1980-07-04       Impact factor: 56.272

4.  Short-term effects of felodipine, a new dihydropyridine, in hypertension.

Authors:  O Andersson; C Bengtsson; D Elmfeldt; K Haglund; T Hedner; P Seideman; K H Sjöberg; E Strömgren; H Aberg; J Ostman
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

5.  Acute diuretic/natriuretic properties of felodipine in man.

Authors:  B Edgar; B Bengtsson; D Elmfeldt; P Lundborg; G Nyberg; S Raner; O Rönn
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  Vascular selectivity of felodipine.

Authors:  B Ljung
Journal:  Drugs       Date:  1985       Impact factor: 9.546

7.  Effects of felodipine on renal function in animals.

Authors:  G F DiBona
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Experience with nitrendipine--a new calcium antagonist--in hypertension.

Authors:  L Andrén; L Hansson; L Orö; T Ryman
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

9.  Long term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension.

Authors:  P Collste; M Danielsson; D Elmfeldt; E Feleke; A Gelin; T Hedner; L Rydén
Journal:  Drugs       Date:  1985       Impact factor: 9.546

10.  Felodipine. A calcium-inhibiting vasodilator in refractory hypertension.

Authors:  O K Andersson; G Granérus; T Hedner
Journal:  Drugs       Date:  1985       Impact factor: 9.546

View more
  17 in total

1.  Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.

Authors:  E Blychert; K Wingstrand; B Edgar; K Lidman
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

2.  Short and long term treatment of essential hypertension with felodipine as monotherapy.

Authors:  K Harrington; P Fitzgerald; P O'Donnell; K W Hill; E O'Brien; K O'Malley
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

4.  Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.

Authors:  P H Dunselman; B Edgar; A H Scaf; C E Kuntze; H Wesseling
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

5.  Pharmacokinetics of felodipine in patients with impaired renal function.

Authors:  B Edgar; C G Regårdh; P O Attman; M Aurell; H Herlitz; G Johnsson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 6.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

7.  Glucose tolerance in hypertensive patients during treatment with the calcium antagonist, felodipine.

Authors:  T Hedner; D Elmfeldt; H Von Schenck; E Sjögren; U Smith
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

Review 8.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

9.  Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo.

Authors:  A Bossini; C Di Veroli; G Cavallotti; V Cagli
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 10.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.